Peter Burfeind

5.7k total citations · 1 hit paper
102 papers, 3.9k citations indexed

About

Peter Burfeind is a scholar working on Genetics, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Peter Burfeind has authored 102 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Genetics, 48 papers in Molecular Biology and 14 papers in Reproductive Medicine. Recurrent topics in Peter Burfeind's work include Genomic variations and chromosomal abnormalities (18 papers), Sperm and Testicular Function (13 papers) and Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (11 papers). Peter Burfeind is often cited by papers focused on Genomic variations and chromosomal abnormalities (18 papers), Sperm and Testicular Function (13 papers) and Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (11 papers). Peter Burfeind collaborates with scholars based in Germany, United States and Poland. Peter Burfeind's co-authors include Hans‐Ulrich Pauer, Thomas Renné, Bernhard Nieswandt, David Gailani, Kai Schuh, Paul Thelen, Bernhard Hemmerlein, Sabine Grüner, Miroslava Požgajová and Frauke Rininsland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Immunity.

In The Last Decade

Peter Burfeind

102 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Defective thrombus formation in mice lacking coagulation factor XII

2005 537 citations Thomas Renné, Miroslava Požgajová et al. The Journal of Experimental Medicine profile →

Peers

Countries citing papers authored by Peter Burfeind

Since Specialization

Citations

This map shows the geographic impact of Peter Burfeind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Burfeind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Burfeind more than expected).

Fields of papers citing papers by Peter Burfeind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Burfeind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Burfeind. The network helps show where Peter Burfeind may publish in the future.

Co-authorship network of co-authors of Peter Burfeind

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Burfeind. A scholar is included among the top collaborators of Peter Burfeind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Burfeind. Peter Burfeind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phenotypic spectrum of BLM ‐ and RMI1 ‐related Bloom syndrome 2022 ·Clinical Genetics ·(unknown), Nursel Elçioğlu, (unknown), (unknown), (unknown), (unknown), Janine Altmüller, Silke Kaulfuß, Yun Li, Peter Nürnberg, Peter Burfeind, Gökhan Yiğit, Bernd Wollnik	8
2	Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death 2017 ·Cancer Letters ·(unknown), (unknown), (unknown), Margret Rave‐Fränk, Felix Bremmer, (unknown), Lena‐Christin Conradi, Jens‐Gerd Scharf, Peter Burfeind, Silke Kaulfuß	16
3	High-grade acute organ toxicity and p16INK4A expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma 2015 ·Strahlentherapie und Onkologie ·(unknown), Julia Kitz, Margret Rave‐Fränk, Stephan Lorenzen, Li Li, Stefan Küffer, Clemens F. Hess, Peter Burfeind, Holger M. Reichardt, Martin Canis, Tim Beißbarth, Hendrik A. Wolff	17
4	Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma 2015 ·Strahlentherapie und Onkologie ·Margret Rave‐Fränk, (unknown), Julia Kitz, Martin Leu, (unknown), Peter Burfeind, Henning Schliephake, Martin Canis, Tim Beißbarth, Holger M. Reichardt, Hendrik A. Wolff	21
5	Branchio-Otic Syndrome Caused by a Genomic Rearrangement: Clinical Findings and Molecular Cytogenetic Studies in a Patient with a Pericentric Inversion of Chromosome 8 2013 ·Cytogenetic and Genome Research ·Thomas M. Schmidt, Tatjana Bierhals, Fanny Kortüm, Iris Bartels, Thomas Liehr, Peter Burfeind, Moneef Shoukier, Valeska Frank, Carsten Bergmann, Kerstin Kutsche	18
6	Discordant phenotype in monozygotic twins with mosaic trisomy 12p in lymphocytes 2012 ·European Journal of Medical Genetics ·Silke Pauli, Thomas M. Schmidt, (unknown), Barbara Zoll, Peter Burfeind, (unknown), Moneef Shoukier, Iris Bartels	9
7	Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D 2012 ·American Journal of Medical Genetics Part A ·Silke Pauli, Doris Steinemann, (unknown), Jürgen Wienands, Moneef Shoukier, (unknown), Peter Burfeind, Georgi Manukjan, Gudrun Göhring, Gabriele Escherich	10
8	Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis 2009 ·Molecular Cancer Therapeutics ·(unknown), Peter Burfeind, Jochen Gaedcke, Jens‐Gerd Scharf	59
9	Targeted Disruption of the Mouse <i>Npal3</i> Gene Leads to Deficits in Behavior, Increased IgE Levels, and Impaired Lung Function 2009 ·Cytogenetic and Genome Research ·Paweł Grzmil, J Konietzko, (unknown), (unknown), Alicia Aguilar, Anahita Javaheri, Svetoslav Kalaydjiev, Thure Adler, Ines Bolle, Ibrahim M. Adham, C. Dixkens, Stephan Wolf, Helmut Fuchs, (unknown), Wolfgang Wurst, Markus Ollert, Dirk H. Busch, Heidi L. Schulz, Martin Hrabě de Angelis, Peter Burfeind	7
10	Proven germline mosaicism in a father of two children with CHARGE syndrome 2009 ·Clinical Genetics ·Silke Pauli, (unknown), Johannes Häberle, Paweł Grzmil, Peter Burfeind, (unknown), (unknown), (unknown)	23
11	Identification of subtelomeric genomic imbalances and breakpoint mapping with quantitative PCR in 296 individuals with congenital defects and/or mental retardation 2009 ·Molecular Cytogenetics ·Bernd Auber, (unknown), Barbara Zoll, Peter Burfeind, (unknown), Thomas Liehr, Knut Brockmann, Ekkehard Wilichowski, (unknown), Iris Bartels	7
12	Defective thrombus formation in mice lacking coagulation factor XII breakdown → 2005 ·The Journal of Experimental Medicine ·Thomas Renné, Miroslava Požgajová, Sabine Grüner, Kai Schuh, Hans‐Ulrich Pauer, Peter Burfeind, David Gailani, Bernhard Nieswandt	537
13	Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo 2004 ·Thrombosis and Haemostasis ·Hans‐Ulrich Pauer, Thomas Renné, Bernhard Hemmerlein, Tobias J. Legler, (unknown), Ibrahim M. Adham, Werner Müller‐Esterl, Guenter Emons, U. Sancken, Wolfgang Engel, Peter Burfeind	103
14	Factor XII deficiency is strongly associated with primary recurrent abortions 2003 ·Fertility and Sterility ·Hans‐Ulrich Pauer, Peter Burfeind, H. Köstering, Günter Emons, B. Hinney	43
15	Uterine Cervical Metastasis of Breast Cancer: A Rare Complication that May be Overlooked 2003 ·Oncology Research and Treatment ·Hans‐Ulrich Pauer, Volker Viereck, Peter Burfeind, (unknown), Thomas F. Krauss	13
16	Bax Inhibitor-1 Is Overexpressed in Prostate Cancer and Its Specific Down-Regulation by RNA Interference Leads to Cell Death in Human Prostate Carcinoma Cells 2003 ·American Journal Of Pathology ·Michal Grzmil, Paul Thelen, Bernhard Hemmerlein, Stefan Schweyer, (unknown), (unknown), Peter Burfeind	72
17	Isolation and characterization of a novel human gene, NIF3L1, and its mouse ortholog, <i>Nif3l1</i>, highly conserved from bacteria to mammals 2000 ·Cytogenetic and Genome Research ·(unknown), (unknown), C. Dixkens, Karim Nayernia, Wolfgang Engel, Peter Burfeind	15
18	Refinement of the Expression Pattern of a Mouse Homologue of the Porcine 135-kDa α-d-Mannosidase (MAN2B2) 2000 ·Biochemical and Biophysical Research Communications ·(unknown), Karim Nayernia, Wolfgang Engel, Peter Burfeind	4
19	Normal Bronchial Epithelial Cells Constitutively Produce the Anti-Inflammatory Cytokine Interleukin-10, Which is Downregulated in Cystic Fibrosis 1995 ·American Journal of Respiratory Cell and Molecular Biology ·Tracey L. Bonfield, Michael W. Konstan, Peter Burfeind, James R. Panuska, Jay B. Hilliard, Madelyn Berger	288
20	Sequence, expression, and chromosomal assignment of a human sperm outer dense fiber gene 1993 ·Molecular Reproduction and Development ·Oliver Gastmann, Peter Burfeind, (unknown), H. Hameister, Claude Szpirer, Sigrid Hoyer‐Fender	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact